Complement Abnormality, Covid19, Peripheral Blood Mononuclear Cells
Conditions
Brief summary
The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained. Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection. Sample storage and subsequent use in fundamental research will be performed at VUB Neuro-Aging and Viro-Immunotherapy. Additionally, medical records of UZ Brussel will be searched and epidemiological, clinical, radiological, and biological data of the selected patients will be obtained at the diagnosis time point and during follow-up. Healthy volunteers will be recruited as well in the current study, as a comparison arm, after informed consent is obtained.
Interventions
OTHERBlood analysis
Venipuncture and collection of serum and whole blood
Sponsors
Universitair Ziekenhuis Brussel
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
Covid-19 patients Inclusion Criteria: * Positive nasopharyngeal reverse transcriptase-polymerase chain reaction for SARS-Coronavirus-02 * Signed inform consent Healthy Volunteers Inclusion Criteria: * Signed inform consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in complements or peripheral blood mononuclear cells between CoViD-19 patients and controls | up to 1 year |
Countries
Belgium
Contacts
Primary ContactMarco Moretti
Outcome results
None listed